Cytarabine
- Generic Name
- Cytarabine
- Brand Names
- Cytosar, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13N3O5
- CAS Number
- 147-94-4
- Unique Ingredient Identifier
- 04079A1RDZ
- Background
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra P...
- Indication
For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
...
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
- Associated Therapies
- -
Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma
- Conditions
- Childhood Immunoblastic Large Cell LymphomaChildhood Diffuse Large Cell LymphomaStage I Childhood Small Noncleaved Cell LymphomaStage II Childhood Large Cell LymphomaStage II Childhood Small Noncleaved Cell LymphomaStage IV Childhood Small Noncleaved Cell LymphomaStage I Childhood Large Cell LymphomaStage III Childhood Large Cell LymphomaStage IV Childhood Large Cell LymphomaUntreated Childhood Acute Lymphoblastic Leukemia
- Interventions
- Drug: doxorubicin hydrochlorideDrug: cyclophosphamideDrug: methotrexateDrug: leucovorin calciumDrug: rasburicaseDrug: prednisoneDrug: methylprednisoloneBiological: filgrastimBiological: rituximabDrug: cytarabineDrug: etoposideDrug: vincristine sulfateDrug: hydrocortisone sodium succinateOther: laboratory biomarker analysis
- First Posted Date
- 2003-04-09
- Last Posted Date
- 2014-09-19
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 97
- Registration Number
- NCT00057811
- Locations
- 🇺🇸
Children's Oncology Group, Arcadia, California, United States
Anti-Human CD45 Monoclonal Antibodies in Patients With Advanced Leukemia Prior to Allogeneic Stem Cell Transplantation
- Conditions
- Interventions
- First Posted Date
- 2003-03-28
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 6
- Registration Number
- NCT00057005
- Locations
- 🇺🇸
The Methodist Hospital, Houston, Texas, United States
🇺🇸Texas Children's Hospital, Houston, Texas, United States
Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
- Conditions
- First Posted Date
- 2003-03-07
- Last Posted Date
- 2018-05-03
- Lead Sponsor
- Heidelberg University
- Target Recruit Count
- 1551
- Registration Number
- NCT00055874
- Locations
- 🇩🇪
Kreiskrankenhaus Aurich, Aurich, Germany
🇩🇪Krankenhaus / Klinikum Krefeld, Aachen, Germany
🇩🇪Haematologisch-Onkologische Schwerpunktpraxis, Berlin, Germany
Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2013-07-24
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 34
- Registration Number
- NCT00054327
- Locations
- 🇺🇸
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Bryostatin 1 and Cytarabine in Treating Patients With Relapsed Acute Myelogenous Leukemia
- Conditions
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2010-03-01
- Lead Sponsor
- Virginia Commonwealth University
- Registration Number
- NCT00017342
- Locations
- 🇺🇸
Herbert Irving Comprehensive Cancer Center at Columbia University, New York, New York, United States
🇺🇸University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸New York Weill Cornell Cancer Center at Cornell University, New York, New York, United States
Irinotecan and Cytarabine in Treating Patients With Refractory or Recurrent Acute Myeloid Leukemia or Chronic Myelogenous Leukemia
- Conditions
- First Posted Date
- 2003-01-28
- Last Posted Date
- 2011-03-08
- Lead Sponsor
- Roswell Park Cancer Institute
- Registration Number
- NCT00053144
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2003-01-28
- Last Posted Date
- 2009-07-07
- Lead Sponsor
- Theradex
- Registration Number
- NCT00053105
- Locations
- 🇺🇸
Arizona Clinical Research Center, Tucson, Arizona, United States
🇺🇸Highlands Oncology Group, Springdale, Arkansas, United States
🇺🇸USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
Combination Chemotherapy Followed By Filgrastim or Sargramostim in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
- Conditions
- First Posted Date
- 2003-01-28
- Last Posted Date
- 2011-03-08
- Lead Sponsor
- Roswell Park Cancer Institute
- Registration Number
- NCT00053131
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Combination Chemotherapy With or Without Donor Bone Marrow Transplantation in Treating Infants With Previously Untreated Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Drug: asparaginaseDrug: cyclophosphamideDrug: cyclosporineDrug: cytarabineDrug: daunorubicin hydrochlorideDrug: dexamethasoneDrug: doxorubicin hydrochlorideDrug: mercaptopurineDrug: methotrexateDrug: methylprednisoloneDrug: pegaspargaseDrug: thioguanineDrug: vincristine sulfateProcedure: allogeneic bone marrow transplantationRadiation: radiation therapy
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-02-20
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 6
- Registration Number
- NCT00022126
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Emory University Hospital - Atlanta, Atlanta, Georgia, United States
🇺🇸Loma Linda University Medical Center, Loma Linda, California, United States
Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Acute Leukemia
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-10-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 53
- Registration Number
- NCT00016016
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.